Share-based Payment Arrangement, Expense of Monte Rosa Therapeutics, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Monte Rosa Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Monte Rosa Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,364,000, a 1.9% increase year-over-year.
  • Monte Rosa Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $19,025,000.
  • Monte Rosa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $18,126,000, a 8.7% increase from 2023.
  • Monte Rosa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $16,669,000, a 43% increase from 2022.
  • Monte Rosa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11,664,000, a 124% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Monte Rosa Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $19,025,000 $4,364,000 +$82,000 +1.9% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $18,943,000 $4,894,000 +$392,000 +8.7% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $18,551,000 $5,298,000 +$425,000 +8.7% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $18,126,000 $4,469,000 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $4,282,000 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $4,502,000 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $4,873,000 +$899,000 +23% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q1 2023 $3,974,000 +$1,723,000 +77% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $2,251,000 +$1,999,000 +793% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q2 2021 $1,271,000 +$1,163,000 +1077% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $252,000 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q2 2020 $108,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2

Monte Rosa Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $18,126,000 +$1,457,000 +8.7% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $16,669,000 +$5,005,000 +43% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $11,664,000 +$6,464,000 +124% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $5,200,000 +$4,846,000 +1369% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $354,000 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.